| Pitfalls in Assessing Response to Treatment in MDS |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes |
|
Journal of Patient-Reported Outcomes |
Myelodysplastic Syndromes (MDS) |
| Guideline-based indicators for adult patients with myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium |
|
Pediatric Blood & Cancer |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Pediatric |
| A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes |
|
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation |
Myelodysplastic Syndromes (MDS) |
| Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes |
|
Cancer |
Myelodysplastic Syndromes (MDS) |
| Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes |
|
Cancer |
Myelodysplastic Syndromes (MDS) |
| Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges |
|
International Journal of Laboratory Hematology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes |
|
Nature Medicine |
Myelodysplastic Syndromes (MDS) |
